헌터증후군 치료 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of Hunter syndrome treatment Market

The global Hunter syndrome treatment market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, reaching USD 1.81 billion by 2034, registering a CAGR of 6.20% during 2026-2034.

North America dominated the global market with a 50.84% market share in 2025, supported by strong reimbursement frameworks, higher diagnosis rates, and the presence of major biopharmaceutical players.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare inherited lysosomal storage disorder caused by the body's inability to break down mucopolysaccharides. The disease primarily affects males and can significantly shorten life expectancy if untreated. Increasing R&D investments and clinical trials targeting neurological complications are shaping market expansion.

Market Trends

Rising R&D Investments in Rare Diseases

A significant trend influencing the market is the growing investment in orphan drug research. Several clinical-stage biotechnology companies are developing advanced therapies, including gene therapies and brain-penetrant enzyme treatments.

Companies such as:

• ArmaGen
• REGENXBIO Inc.
• Denali Therapeutics

are actively advancing pipeline candidates.

Rare diseases often receive regulatory advantages such as faster approvals and market exclusivity. Compared to traditional chronic diseases like diabetes or coronary artery disease, orphan drug approvals require smaller outcome studies, making the segment attractive for innovation.

Market Drivers

1. Unmet Clinical Needs

Currently, only two approved therapies dominate the market:

• Elaprase
• Hunterase

Elaprase remains the primary treatment globally but is expensive and inaccessible to many patients in emerging economies. Hunterase is approved in select countries but also remains costly.

Additionally, current enzyme replacement therapies (ERTs) cannot cross the blood-brain barrier, leaving neurological symptoms untreated. Approximately two-thirds of patients suffer severe neurological complications, creating demand for next-generation therapies capable of addressing central nervous system involvement.

2. Strong Pipeline Presence

According to the Genetic and Rare Diseases Information Center (GARD), nearly 7,000 rare diseases affect 25-30 million individuals in the U.S. This has accelerated R&D in rare disorders like MPS II.

Pipeline expansion and growing clinical trial activity are expected to drive substantial market growth through 2034.

Market Restraints

High Treatment Costs & Low Access in Emerging Markets

The major restraint remains the high cost of enzyme replacement therapies. In many emerging countries, reimbursement support is limited, awareness is low, and treatment access remains inadequate. As a result, a large proportion of diagnosed patients remain untreated.

Segmentation Analysis

By Treatment

The market is segmented into:

• Enzyme Replacement Therapy (ERT)
• Others (Gene therapy, HSCT, emerging modalities)

ERT dominated the market and is projected to account for 93.38% share in 2026. Both Elaprase and Hunterase are ERTs, maintaining segment leadership.

The "Others" segment is expected to grow at a higher CAGR due to advancements in gene therapy and hematopoietic stem cell transplant (HSCT).

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)/Intrathecal

The intravenous segment is expected to hold 97.46% market share in 2026, primarily due to Elaprase's intravenous administration route.

By End User

• Hospitals
• Specialty Clinics
• Others

Hospitals are projected to hold 61.70% market share in 2026, as intravenous ERT administration requires specialized medical supervision.

Regional Analysis

North America

North America recorded USD 0.54 billion in 2025 and USD 0.57 billion in 2026. The region led the market due to high diagnosis rates, strong reimbursement systems, and active clinical pipelines.

The U.S. market alone is expected to reach USD 0.53 billion by 2026.

Asia Pacific

Asia Pacific is projected to register a higher CAGR during the forecast period. Japan benefits from Hunterase availability, while China and India represent underpenetrated markets.

By 2026:

• Japan: USD 0.10 billion
• China: USD 0.03 billion
• India: USD 0.07 billion

Europe

Europe is expected to witness steady growth due to favorable rare disease policies and increasing adoption of advanced therapies.

Competitive Landscape

The market remains largely monopolistic, dominated by:

• Shire (now part of Takeda Pharmaceutical Company Limited)

Elaprase's strong clinical performance and global approval maintain Takeda's leading position.

Other key companies include:

• JCR Pharmaceuticals Co., Ltd.
• Green Cross Corp.
• CANbridge Life Sciences Ltd.
• Sangamo Therapeutics
• Inventiva

Key Industry Developments

• July 2021 - Denali Therapeutics announced positive clinical data for ETV:IDS, a brain-penetrant enzyme therapy.
• May 2021 - Inventiva presented updates on oral small molecule therapies for MPS disorders.
• March 2018 - Shire partnered with NanoMedSyn to explore advanced enzyme replacement therapies.

Conclusion

The global Hunter syndrome treatment market is poised for steady growth from USD 1.05 billion in 2025 to USD 1.81 billion by 2034, driven by increasing R&D investments, unmet neurological treatment needs, and expanding orphan drug pipelines. While high therapy costs and limited access in emerging economies remain major restraints, innovation in gene therapy and brain-penetrant treatments is expected to transform the competitive landscape.

Segmentation By Treatment

• Enzyme Replacement Therapy (ERT)
• Others

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)/ Intrathecal

By End User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
• Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Pipeline Analysis
• 4.2. Key Industry Developments
• 4.3. Regulatory Scenario by Key Regions
• 4.4. Overview of Emerging Treatments for Hunter Syndrome
• 4.5. Reimbursement Scenario by Key Regions

5. Global Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Treatment
  • 5.2.1. Enzyme Replacement Therapy (ERT)
  • 5.2.2. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Intravenous
  • 5.3.2. Intracerebroventricular (ICV)/ Intrathecal
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals
  • 5.4.2. Specialty Clinics
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Treatment
  • 6.2.1. Enzyme Replacement Therapy (ERT)
  • 6.2.2. Others
• 6.3. Market Analysis - By Route of Administration
  • 6.3.1. Intravenous
  • 6.3.2. Intracerebroventricular (ICV)/ Intrathecal
• 6.4. Market Analysis - By End User
  • 6.4.1. Hospitals
  • 6.4.2. Specialty Clinics
  • 6.4.3. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Treatment
  • 7.2.1. Enzyme Replacement Therapy (ERT)
  • 7.2.2. Others
• 7.3. Market Analysis - By Route of Administration
  • 7.3.1. Intravenous
  • 7.3.2. Intracerebroventricular (ICV)/ Intrathecal
• 7.4. Market Analysis - By End User
  • 7.4.1. Hospitals
  • 7.4.2. Specialty Clinics
  • 7.4.3. Others
• 7.5. Market Analysis - By Country/ sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Rest of Europe

8. Asia pacific Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Treatment
  • 8.2.1. Enzyme Replacement Therapy (ERT)
  • 8.2.2. Others
• 8.3. Market Analysis - By Route of Administration
  • 8.3.1. Intravenous
  • 8.3.2. Intracerebroventricular (ICV)/ Intrathecal
• 8.4. Market Analysis - By End User
  • 8.4.1. Hospitals
  • 8.4.2. Specialty Clinics
  • 8.4.3. Others
• 8.5. Market Analysis - By Country/ sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. South Korea
  • 8.5.5. Rest of Asia Pacific

9. Rest of the World Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Treatment
  • 9.2.1. Enzyme Replacement Therapy (ERT)
  • 9.2.2. Others
• 9.3. Market Analysis - By Route of Administration
  • 9.3.1. Intravenous
  • 9.3.2. Intracerebroventricular (ICV)/ Intrathecal
• 9.4. Market Analysis - By End User
  • 9.4.1. Hospitals
  • 9.4.2. Specialty Clinics
  • 9.4.3. Others

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2017)
• 10.3. Competition Dashboard
• 10.4. Comparative Analysis - Major Players
• 10.5. Company Profiles
  • 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
    • 10.5.1.1. Overview,
    • 10.5.1.2. Products & services,
    • 10.5.1.3. SWOT analysis,
    • 10.5.1.4. Recent developments,
    • 10.5.1.5. strategies,
    • 10.5.1.6. financials (based on availability)
  • 10.5.2. Denali Therapeutics
    • 10.5.2.1. Overview,
    • 10.5.2.2. Products & services,
    • 10.5.2.3. SWOT analysis,
    • 10.5.2.4. Recent developments,
    • 10.5.2.5. strategies,
    • 10.5.2.6. financials (based on availability)
  • 10.5.3. ArmaGen
    • 10.5.3.1. Overview,
    • 10.5.3.2. Products & services,
    • 10.5.3.3. SWOT analysis,
    • 10.5.3.4. Recent developments,
    • 10.5.3.5. strategies,
    • 10.5.3.6. financials (based on availability)
  • 10.5.4. Inventiva
    • 10.5.4.1. Overview,
    • 10.5.4.2. Products & services,
    • 10.5.4.3. SWOT analysis,
    • 10.5.4.4. Recent developments,
    • 10.5.4.5. strategies,
    • 10.5.4.6. financials (based on availability)
  • 10.5.5. Green Cross Corp. (GC Pharma)
    • 10.5.5.1. Overview,
    • 10.5.5.2. Products & services,
    • 10.5.5.3. SWOT analysis,
    • 10.5.5.4. Recent developments,
    • 10.5.5.5. strategies,
    • 10.5.5.6. financials (based on availability)
  • 10.5.6. CANbridge Life Sciences Ltd.
    • 10.5.6.1. Overview,
    • 10.5.6.2. Products & services,
    • 10.5.6.3. SWOT analysis,
    • 10.5.6.4. Recent developments,
    • 10.5.6.5. strategies,
    • 10.5.6.6. financials (based on availability)
  • 10.5.7. JCR Pharmaceuticals Co., Ltd.
    • 10.5.7.1. Overview,
    • 10.5.7.2. Products & services,
    • 10.5.7.3. SWOT analysis,
    • 10.5.7.4. Recent developments,
    • 10.5.7.5. strategies,
    • 10.5.7.6. financials (based on availability)
  • 10.5.8. REGENXBIO Inc.
    • 10.5.8.1. Overview,
    • 10.5.8.2. Products & services,
    • 10.5.8.3. SWOT analysis,
    • 10.5.8.4. Recent developments,
    • 10.5.8.5. strategies,
    • 10.5.8.6. financials (based on availability)
  • 10.5.9. Sangamo Therapeutics
    • 10.5.9.1. Overview,
    • 10.5.9.2. Products & services,
    • 10.5.9.3. SWOT analysis,
    • 10.5.9.4. Recent developments,
    • 10.5.9.5. strategies,
    • 10.5.9.6. financials (based on availability)

11. Strategic Recommendation